Article
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
All News
Article
In difficult times, it's reassuring to reflect on the similarities that bring us together. In the case of the EULAR and ACR COVID19 guidelines as discussed at #EULAR2020 by Drs.
Article
A Lancet systematic review and meta-analysis provides the basis for physical distancing and the value of making as measures to prevent infection with coronavirus 2 (SARS-CoV-2) or COVID-19.
The analysis included 172 observational studies, no randomised controlled trials and 44 relevant comparative studies involving 25 697 patients.
Article
NEJM has reported that the use of hydroxychloroquine did not prevent symptomatic COVID-19 infection when used within 4 days after SARS-CoV-2 exposure.
Currently for persons who are COVID exposed, the standard of care is quarantine and there is no known preventative therapy.
Article
This week's Tuesday Nite Rheumatology featured Dr Jonathan Kay (U Mass) who gave an update on Biosimilars and took questions the subject. The program was moderated by Dr. Jack Cush.
Article
Almost one-third of patients with new-onset rheumatoid arthritis (RA) reported persistent unacceptable pain after 21 months of combination therapy, according to a study by Swedish researchers.A total of 29% of patients continued to have unacceptable pain.
Article
Today Eli Lilly announced that Taltz (ixekizumab) has received FDA approval for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
Article
Gianfresco et al have published the first peer-reviewed analysis of COVID-19 infected, rheumatic disease patients entered into the Rheumatology Global Alliance registry; showing that a) rheumatic disease patient can be infected with COVID-19, b) that DMARD and biologic use has no apparent effect on outcomes and c) steroid increase and TNF inhibitor decrease the odds of hospitalization.
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Article
The Wnt pathway modulator lorecivivint failed to meet the primary endpoint in a phase IIa study for knee osteoarthritis (OA), but showed promise in certain patient subgroups, researchers reported.
Article
This week's Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama - Birmingham as he spoke and took questions on the immunology, immunopathogenesis and treatment of Cytokine Storm Syndrome, especially as they relate to COVID-19 and rheumatic disease patients. The program was moderated by Dr. Jack Cush.
k dao
Tweet
#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs
k dao
Tweet
#EULAR2020 OP0160 Prospective study of Hopkins Lupus Cohort: HCQ blood levels can predict risk for thrombotic events in SLE. Dr. M Petri advocates this is another reason for monitoring HCQ whole blood levels. Goal HCQ whole blood level should be 1000-1500 ng/mL @rheumnow https://t.co/mM6jsJ2Qmf
Dr. Rachel Tate
Tweet
This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4
k dao
Tweet
Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI
Janet Pope
Tweet
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
k dao
Tweet
#EULAR2020 OP0167 Results are finally in!!
MMF can be safely w/drawn in quiescent SLE: prospect RCT (nonblinded) 102 pts. MMF tapered over 12 weeks, f/u 60 weeks; no sig diff for flares in pts who stopped MMF vs. maintained; pts who cont MMF had ⬆️ minor infections. @rheumnow https://t.co/bOnuEBLis9
Dr. John Cush
Tweet
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
Dr. John Cush
Tweet
UPI quotes Dr. Tony Fauci stating (about hydroxychloroquine) "The scientific data is really quite evident now about the lack of efficacy". Yesterday France and other countries have banned the use of HCQ to treat COVID. https://t.co/G0EuWMGTdW
Dr. John Cush
Tweet
CORRONA registry compared Triple DMARD (MSH) to TNF/MTX Rx; MSH is infrequently used; Triple DMARD pts were older, longer Dz duration, less Dz activity, more CA & comorbidities. Comparatively MSH had more Discontinuations & less likely to get to LDAS https://t.co/WSHgzrfcIn
